NCT06744361 Ketamine Sedation As Neuroprotective Agent Following Out-of-hospital Cardiac Arrest
| NCT ID | NCT06744361 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Christian Hassager |
| Condition | Out-of-hospital Cardiac Arrest (OHCA) |
| Study Type | INTERVENTIONAL |
| Enrollment | 282 participants |
| Start Date | 2024-12-12 |
| Primary Completion | 2027-09-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 282 participants in total. It began in 2024-12-12 with a primary completion date of 2027-09-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
OHCA is a critical medical emergency with significant mortality and morbidity primarily due to hypoxic-ischemic brain injury (HIBI). Despite advances in resuscitation techniques, the neurological outcomes for survivors remain poor. Current post-resuscitation practices lack specific neuroprotective strategies. Ketamine, an N-Methyl-D-Aspartate (NMDA) receptor antagonist, has shown potential neuroprotective properties in preclinical and clinical studies due to its ability to inhibit excitotoxicity and reduce neuronal apoptosis. This trial hypothesizes that ketamine, when used for sedation in OHCA patients, may offer superior neuroprotective benefits compared to the commonly used sedative propofol. By comparing the effects of ketamine and propofol on neuronal damage markers and long-term neurological outcomes, this study aims to identify a potentially effective intervention to improve the prognosis of OHCA patients.
Eligibility Criteria
Inclusion Criteria: * Adults (age ≥18 years) AND * resuscitated OHCA of presumed cardiac cause with a shockable first recorded heart rhythm AND * mean arterial pressure (MAP) \>40 mmHg AND * a decision to perform prehospital intubation. Exclusion Criteria: * Advanced life support termination-of-resuscitation (TOR) criteria met * Systolic blood pressure \>190 mmHg * Known allergy to ketamine or propofol * Chronic diseases making 180-day survival unlikely * Body temperature \<30° C.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06744361 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Out-of-hospital Cardiac Arrest (OHCA). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06744361 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06744361 currently recruiting?
Yes, NCT06744361 is actively recruiting participants. Contact the research team at salma.charabi@regionh.dk for enrollment information.
Where is the NCT06744361 trial being conducted?
This trial is being conducted at Copenhagen, Denmark, Odense C, Denmark.
Who is sponsoring the NCT06744361 clinical trial?
NCT06744361 is sponsored by Christian Hassager. The trial plans to enroll 282 participants.